VERO Biotech Secures $50 Million Funding from Runway Growth Capital
A senior secured term loan will support the further development…
FDA Approves Interhospital Patient Transport Use of VERO Biotech’s GENOSYL® Delivery System, Resulting in the Broadest Label in the Inhaled Nitric Oxide Space
The GENOSYL® DS facilitates patient treatment in interhospital…
Home Use of GENOSYL® Delivery System (DS) to Administer GENOSYL® (nitric oxide) gas for Inhalation for the Treatment of Pulmonary Hypertension Complicated by COVID-19 Infection Published in American Journal of Respiratory and Critical Care Medicine
Clinicians report on first at-home treatment of COVID-19 patient…
VERO Biotech Commits to Atlanta Healthcare Providers, Patients and Workforce During COVID-19 Pandemic
Atlanta-based biotech provides innovative portable inhaled nitric…
VERO Biotech Announces First Patient With COVID-19 Infection Complicating Pulmonary Hypertension Treated with GENOSYL® DS, the First and Only FDA-Approved Tankless System for the Delivery of Inhaled Nitric Oxide
Treatment informs FDA approval for emergency expanded access…
VERO Biotech, Leaders in the Development of Innovative Technologies for Inhaled Nitric Oxide Delivery, to Present at Biotech Showcase 2020
Prestigious investor conference runs concurrently with 38th Annual…
VERO Biotech Receives US FDA Approval of GENOSYL® for the Delivery of Inhaled Nitric Oxide
The GENOSYL® inhaled nitric oxide approval represents the…